CatalystEarnings

$BMRN (BIOMARIN PHARMACEUTICAL) — 8-K: BMRN Q2 FY26 EPS $1.20 smashes consensus by 25.8%

BMRN

$66.17

+2.04%

What changed

Adjusted EPS of $1.20 beat the $0.95 consensus by $0.25 (+25.8%). Revenue rose 19.9% YoY to $990M. FY2026 guidance calls for adjusted EPS of $4.90–$5.10 on revenue of $3.9B.

Why it matters

Adjusted EPS of $1.20 beat the $0.95 consensus by $0.25 (+25.8%). Revenue rose 19.9% YoY to $990M. FY2026 guidance calls for adjusted EPS of $4.90–$5.10 on revenue of $3.9B.

Sources

sec